Repligen (NASDAQ:RGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Key Points

• Repligen posted Q1 EPS of $0.48 versus consensus $0.38 and revenue of $194.3M (up 14.8% YoY), and raised FY2026 guidance to $1.97–$2.05.
• Management launched a Transformation Office to drive cost, manufacturing and IT/AI improvements targeting at least 1 point of annualized margin benefit by end‑2027 and a path to 30% adjusted EBITDA by 2030, while divesting the loss-making Polymem (‑~$7M FY revenue) and expanding China OEM partnerships as China revenue nearly doubled.
• The stock jumped about 7.7% on the results to $127.26, and analysts maintain a "Moderate Buy" consensus with an average price target of $170.25.

Repligen (NASDAQ:RGEN - Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10, FiscalAI reports. The company had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The firm's revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.39 EPS. Repligen updated its FY 2026 guidance to 1.970-2.050 EPS.

Here are the key takeaways from Repligen's conference call:

• Repligen reported strong Q1 results with $194M revenue (15% reported, 11% organic), 160 bps adjusted operating margin expansion, and raised full‑year adjusted EPS guidance to $1.97–$2.05.
• Management launched a Transformation Office to accelerate cost, manufacturing and IT/AI improvements, targeting at least 1 point of annualized margin benefit by end‑2027 and advancing the path to 30% adjusted EBITDA by 2030 (with ~$5–6M of non‑recurring charges).
• China and Asia Pacific momentum picked up meaningfully—China revenues nearly doubled in Q1 and the company signed an OEM partnership to expand local manufacturing and competitiveness beginning in 2027.
• Franchise strength was broad‑based and higher‑margin—analytics grew 50%+ (now guided to 20%+ for 2026), chromatography rose >25% (now guided >20%), and proteins delivered mid‑teens growth with expectations of low double‑digit growth for the year.
• Filtration/ATF growth was moderated for 2026 due to specific customer timing and a gene‑therapy headwind; the divestiture of the loss‑making Polymem business removes about $7M of FY revenue even as it improves margin outlook.

Repligen Stock Up 7.7%

RGEN traded up $9.05 during trading on Tuesday, hitting $127.26. 1,075,719 shares of the company's stock were exchanged, compared to its average volume of 869,476. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The business's 50 day moving average is $121.56 and its two-hundred day moving average is $144.68. Repligen has a fifty-two week low of $109.50 and a fifty-two week high of $175.77. The stock has a market cap of $7.18 billion, a P/E ratio of 149.91, a PEG ratio of 2.28 and a beta of 1.09.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. UMB Bank n.a. raised its holdings in Repligen by 13.8% during the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company's stock worth $124,000 after buying an additional 92 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company's stock worth $4,542,000 after buying an additional 100 shares during the last quarter. Itau Unibanco Holding S.A. raised its holdings in Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company's stock worth $62,000 after buying an additional 104 shares during the last quarter. Cerity Partners LLC raised its holdings in Repligen by 6.1% during the fourth quarter. Cerity Partners LLC now owns 2,718 shares of the biotechnology company's stock worth $445,000 after buying an additional 157 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in Repligen by 15.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,327 shares of the biotechnology company's stock worth $221,000 after buying an additional 175 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

RGEN has been the topic of several research reports. Wells Fargo & Company decreased their price target on shares of Repligen from $190.00 to $180.00 and set an "overweight" rating on the stock in a report on Wednesday, February 25th. Weiss Ratings lowered shares of Repligen from a "hold (c-)" rating to a "sell (d+)" rating in a report on Tuesday, March 3rd. UBS Group decreased their price target on shares of Repligen from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Wednesday, February 25th. KeyCorp reaffirmed an "overweight" rating on shares of Repligen in a report on Wednesday, February 25th. Finally, Rothschild & Co Redburn set a $160.00 price target on shares of Repligen and gave the company a "buy" rating in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $170.25.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.